Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial-Reference-Cited by-同舟云学术

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Published:2015-03 Issue:3 Volume:16 Page:257-265
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rizvi Naiyer A,Mazières Julien,Planchard David,Stinchcombe Thomas E,Dy Grace K,Antonia Scott J,Horn Leora,Lena Hervé,Minenza Elisa,Mennecier Bertrand,Otterson Gregory A,Campos Luis T,Gandara David R,Levy Benjamin P,Nair Suresh G,Zalcman Gérard,Wolf Jürgen,Souquet Pierre-Jean,Baldini Editta,Cappuzzo Federico,Chouaid Christos,Dowlati Afshin,Sanborn Rachel,Lopez-Chavez Ariel,Grohe Christian,Huber Rudolf M,Harbison Christopher T,Baudelet Christine,Lestini Brian J,Ramalingam Suresh S

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Immunotherapy and lung cancer: current developments and novel targeted therapies;Domingues;Immunotherapy,2014

2. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion;Schreiber;Science,2011

3. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

4. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010

5. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

Cited by 1251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In situ reprogramming of tumor-associated macrophages enhances cancer immunotherapy;Nano Today;2024-10

2. Occupational health risk recognition, evaluation, and management of radiation workers in Gansu province, China;Radiation Physics and Chemistry;2024-10

3. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system;Clinical and Experimental Medicine;2024-09-09

4. Clinical features, treatment, and outcome of nivolumab induced cholangitis;Immunopharmacology and Immunotoxicology;2024-09-08

5. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors;Biomedicines;2024-08-12